Dr. Geoffrey Guy is the founder of GW Pharmaceuticals and served as Chairman since 1998. Dr. Guy is the creator of Sativex and Epidiolex and continues to lead innovation and new product discovery through active involvement in scientific innovation, medical research and global drug development for his entire career. Prior to his role at GW, Dr. Guy served as Chairman and Chief Executive of Ethical Holdings plc, a NASDAQ-quoted drug delivery Company (now Amarin Corporation plc, or Amarin), which he founded in 1985 and led to its NASDAQ listing in 1993. He founded Phytopharm plc in 1989, of which he was Chairman until 1997, and led to its London Stock Exchange listing in 1996.

Dr. Guy has been the physician in charge of over 300 clinical studies including first dose in man, pharmacokinetics, pharmacodynamics, dose-ranging, controlled clinical trials and large scale multi-centered studies and clinical surveys. Geoffrey is author on numerous scientific publications and has contributed to six books. In 2011, Dr. Guy was appointed as Visiting Professor in the School of Science and Medicine at the University of Buckingham in 2011, and at the University of Westminster in 2016. Dr. Guy received the “Deloitte Director of the Year Award in Pharmaceuticals and Healthcare” in 2011. Dr. Guy holds a BSc in pharmacology from the University of London, an MBBS at St Bartholomew’s Hospital, an MRCS Eng and LRCP London, an LMSSA Society of Apothecaries and a Diploma of Pharmaceutical Medicine from the Royal Colleges of Physicians and has been awarded Honorary DSc from University of Reading 2016 for his contributions to science 

Geoffrey is the recipient of our ICRS Lifetime Achievement Award for 2023.